Additional file 14 of Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

Additional file 14: Supplemental file 2: The HRD score and BRCA 1/2 mutation status were used to categorize patients into three groups: patients with a BRCA 1/2 mutation comprised the mutated group, patients wild-type for BRCA 1/2 with a low (≤ 42) (or high > 42) HRD score were respectively classed in the WT HRD-low (WT HRD-high) group.